|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100053357 |
|
最近更新日期: Date of Last Refreshed on: |
2021-11-20 10:07:41 |
|
注册时间: Date of Registration: |
2021-11-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
主观认知衰退问卷量表在早期筛查轻度认知障碍中的价值研究 |
|
Public title: |
The value of the subjective cognitive decline questionnaire9 in early screening for mild cognitive impairment |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
主观认知衰退问卷量表在早期筛查轻度认知障碍中的价值研究 |
|
Scientific title: |
The value of the subjective cognitive decline questionnaire9 in early screening for mild cognitive impairment |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邹敏燕 |
研究负责人: |
柏亚妹 |
|
Applicant: |
Zou Minyan |
Study leader: |
Bai Yamei |
|
申请注册联系人电话: Applicant telephone: |
+8615105165817 |
研究负责人电话:
Study leader's |
13815067378 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2553261052@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
czbym@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市栖霞区仙林大道138号 |
研究负责人通讯地址: |
江苏省南京市栖霞区仙林大道138号 |
|
Applicant address: |
138 Xianlin Dadao, Qixia District, Nanjing City, Jiangsu Province, China |
Study leader's address: |
138 Xianlin Dadao, Qixia District, Nanjing City, Jiangsu Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
210000 |
研究负责人邮政编码: Study leader's postcode: |
210000 |
|
申请人所在单位: |
南京中医药大学护理学院 |
||
|
Applicant's institution: |
School of Nursing, Nanjing University of Chinese Medicine |
||
|
研究负责人所在单位: |
南京中医药大学护理学院 |
||
|
Affiliation of the Leader: |
School of Nursing, Nanjing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021NL-KS079 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
江苏省中医院 |
||
|
Name of the ethic committee: |
Jiangsu Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
张彪 |
||
|
Contact Name of the ethic committee: |
Zhang Biao |
||
|
伦理委员会联系地址: |
江苏省南京市秦淮区汉中路155号 |
||
|
Contact Address of the ethic committee: |
155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
南京中医药大学护理学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Nursing, Nanjing University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市栖霞区仙林大道138号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
138 Xianlin Dadao, Qixia District, Nanjing City, Jiangsu Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
轻度认知障碍 |
||||||||||||||||||||||
|
Target disease: |
Mild cognitive impairment |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
SCD-Q9量表主要运用于识别MCI和主观认知下降主诉。本研究旨在证明SCD-Q9量表评价指标在中国社区老年人群中的有效性,同时评估其对MCI、SCD与健康人群中的鉴别能力,并寻找SCD-9中的核心问题。 |
||||||||||||||||||||||
|
Objectives of Study: |
Subjective cognitive decline questionnaire9 (SCD-Q9) can reliably identify mild cognitive impairment (MCI) with subjective cognitive decline (SCD) complaints. The purpose of this study was to prove the effectiveness of SCD-Q9 in Chinese community elderly population, evaluate its ability to distinguish MCI and SCD from healthy population, and find out the core items in SCD-Q9. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(a)年龄≥60岁;(b)母语为汉语。 |
||||||||||||||||||||||
|
Inclusion criteria |
(a) age ≥60 years;(b) mother tongue is Chinese. |
||||||||||||||||||||||
|
排除标准: |
(a)文盲;(b)严重的视力或听力损害;(c)痴呆或任何可能导致脑功能障碍的身体或精神障碍。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(a) illiteracy;(b) severe impairment of vision or hearing;(c) dementia or any physical or mental disorder that may cause brain dysfunction. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-11-16 00:00:00至 To 2021-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-11-16 00:00:00 至 To 2021-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
未采用随机方法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random methods are not used |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2022年1月31日前采用临床试验公共管理平台向公众开放查询,或向研究者联系索取的方法,公开原始记录的数据和研究计划书。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Before January 31, 2022, the clinical trial public management platform shall be opened to the public for inquiry, or the method of contacting the investigator for request, and the data and research pr |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表为轻度认知障碍记录表。具体在试验结束后上传中国临床试验注册中心平台;电子采集和管理系统采用ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The case record form is the record form of mild cognitive impairment. Upload the details to the platform of China clinical trial registration center after the trial; The electronic capture adopts ResMan. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |